Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1999, p. 2574-2575, Vol. 43, No. 10
Department of Pathology, Hershey Medical
Center, Hershey, Pennsylvania 17033,1 and
Case Western Reserve University, Cleveland, Ohio
441062
Received 8 March 1999/Returned for modification 24 July
1999/Accepted 4 August 1999
Gatifloxacin pneumococcal, staphylococcal and enterococcal
postantibiotic effects (PAEs) were 0.5 to 4.0 h, respectively. For
Escherichia coli and Pseudomonas aeruginosa,
PAEs were 2.2 to 4.8 h. Pneumococcal, staphylococcal, and
enterococcal postantibiotic sub-MIC effects (PA-SMEs) (four times the
MICs) were 3.7 to 8.6, 2.3 to 3.8, and 1.6 h, respectively, and
E. coli and P. aeruginosa PA-SMEs were The postantibiotic effect (PAE) is a
pharmacodynamic parameter that contributes to the choice of antibiotic
dosing regimens. It is defined as length of time that bacterial growth
is suppressed following brief exposure to an antibiotic (2-4,
10). Odenholt-Tornqvist and coworkers have suggested that during
intermittent dosage regimens, suprainhibitory levels of antibiotic are
followed by subinhibitory levels that persist between doses, and they
have hypothesized that persistent sub-MICs extend the PAE (14,
15). The effect of sub-MICs on growth during the PAE period has
been defined as the postantibiotic sub-MIC effect (PA-SME), which
represents the time interval that includes the PAE plus the additional
time during which growth is suppressed by sub-MICs. In contrast to the
PA-SME, SME measures the direct effect of sub-MICs on cultures which
have not been previously exposed to antibiotics (14, 15).
We examined the PAE, PA-SME, and SME of gatifloxacin, a fluoroquinolone
with a wide spectrum of activity (1, 5-9, 16, 17), against
two strains each of penicillin-susceptible, -intermediate, and
-resistant Streptococcus pneumoniae; one Enterococcus
faecalis strain; one methicillin-susceptible Staphylococcus
aureus strain; two methicillin-resistant Staphylococcus
aureus strains (for both of which gatifloxacin MICs were Standard broth microdilution MIC methodology (13) was used.
The PAE was determined by the viable plate count method (4) with Mueller-Hinton broth supplemented with 5% lysed horse blood when
pneumococci were tested. The PAE was induced by exposure for 1 h
to concentrations that were 10 times the MICs for all strains except
the ciprofloxacin-resistant S. aureus isolate and the
P. aeruginosa isolate, for which, to approximate achievable levels in serum (12), concentrations 4 times the MICs were
used. Tubes containing 5 ml of broth with antibiotic were inoculated with approximately 5 × 106 CFU/ml. After 1 h of
exposure, gatifloxacin at 10 times the MIC reduced the starting
inoculum by approximately 1 to 2 log10 units. Growth
controls with inoculum but no antibiotic were included with each
experiment. Tubes were placed in a shaking water bath at 35°C for
1 h. At the end of the exposure period, cultures were diluted
1:1,000 to remove antibiotic. A control containing bacteria preexposed
to antibiotic at a concentration 0.01 times the MIC was also prepared.
Viability counts were determined before exposure and immediately after
dilution (zero time), and then every two hours until tube turbidity
reached a no. 1 McFarland standard. Inocula were prepared by suspending
the overnight growth from a blood agar plate in broth. The broth was
incubated at 35°C for 2 to 4 h in a shaking water bath until
turbidity matched a no. 1 McFarland standard (diluted as required for
inocula), and bacteria were checked for viability by plate counting
(4).
The PAE was defined according to the formula PAE = T In cultures designated for the determination of PA-SME, the PAE was
induced as described above, after exposure to concentrations 4 or 10 times the MICs (see above). Following dilution to 1:1,000, cultures
were divided into four tubes. To three tubes, gatifloxacin was added to
make final subinhibitory concentrations of 0.2, 0.3, and 0.4 times the
MIC. The fourth tube did not receive antibiotic. Viability counts were
determined before exposure, immediately after dilution, and then every
two hours until their turbidity reached a no. 1 McFarland standard. The
PAE was not induced in cultures designated for determination of SME.
The PA-SME was defined according to the formula PA-SME = Tpa All gatifloxacin pneumococcal MICs were 0.25 µg/ml.
Staphylococcal gatifloxacin MICs were 0.06 µg/ml for the
methicillin-susceptible strain. For the ciprofloxacin-susceptible
(0.5 µg/ml) and ciprofloxacin-resistant (16.0 µg/ml)
methicillin-resistant strains, gatifloxacin MICs were 0.06 and 1.0 µg/ml, respectively. The Enterococcus faecalis gatifloxacin MIC was 0.25 µg/ml. The gatifloxacin MIC for E. coli was 0.016 µg/ml, and that for P. aeruginosa was
1.0 µg/ml.
Results are presented in Table 1.
Antibiotic at 0.01 times the MIC had no activity. The mean PAE for the
six pneumococci was 1.8 h, ranging between 1.2 and 4.0 h.
Pneumococcal PA-SMEs were slightly longer than PAEs. At 0.4 times the
MIC, PA-SMEs were 3.7 to 8.6 h, with a mean of 6.9 h.
Pneumococcal PA-SMEs approximated the sum of PAE and SME, indicating
that sub-MICs alone accounted for the slightly longer PA-SMEs.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Postantibiotic Effects of Gatifloxacin against
Gram-Positive and -Negative Organisms
![]()
ABSTRACT
Top
Abstract
Text
References
9.6
and 4.4 h, respectively.
![]()
TEXT
Top
Abstract
Text
References
1.0
µg/ml, but of which one strain was susceptible and one was resistant
to ciprofloxacin); one Escherichia coli strain; and one
Pseudomonas aeruginosa strain. Organisms were identified by
standard methods (11).
C, where T is the time required for viability counts of
an antibiotic-exposed culture to increase by 1 log10 unit
above counts taken immediately after dilution and C is the
corresponding time for the growth control (4).
C, where
Tpa is the time for cultures previously exposed
to antibiotic and then reexposed to different sub-MICs to increase by 1 log10 unit above counts taken immediately after dilution and C is the corresponding time for the unexposed control
(14, 15). The SME was defined according to the formula
SME = Ts
C, where
Ts is the time for the cultures exposed only to
sub-MICs to increase 1 log10 unit above counts taken
immediately after dilution and C is the corresponding time
for the unexposed control. The PA-SME and SME (14, 15) were
measured in two separate experiments. For each experiment, viability
counts (log10 CFU/ml) were plotted against time and results
are expressed as the means of results from two separate assays.
TABLE 1.
PAEs of gatifloxacin against 12 strains
Staphylococcal PAEs were 1.0 to 2.0 h, with a mean of 1.4 h. Staphylococcal PAEs did not differ significantly in ciprofloxacin-susceptible and -resistant methicillin-resistant S. aureus strains. PA-SMEs were longer than PAEs plus SMEs. PA-SMEs at 0.4 times the MIC ranged from 2.3 to 3.8 h, with a mean of 3.3 h. The Enterococcus faecalis strain had a PAE of 0.5 h and a PA-SME at 4 times the MIC of 1.6 h.
For E. coli and P. aeruginosa, PAEs were 4.8 h and 2.2 h, respectively. For E. coli, PA-SMEs were
longer than the PAE plus the PA-SME at 0.2 times the MIC; at 0.3 and
0.4 times the MIC, all SMEs and PA-SMEs were
9.4 h. For the strain of
P. aeruginosa, the PA-SME at 0.4 times the MIC was
4.4 h.
Gatifloxacin MICs were similar to those described previously (1, 5-9, 16, 17). Gatifloxacin, like other quinolones, exhibits rapid concentration-dependent bactericidal activity. Longer intervals between doses may be possible when an antibiotic has a long half-life as well as a prolonged PAE and PA-SME, because regrowth continues to be prevented when levels in serum and tissue fall below MICs (2, 4, 10).
PA-SMEs exceeded the PAE plus the SME at 0.2 times the MIC for the E. coli strain, indicating that, for this organism, gatifloxacin sub-MICs had a greater effect on preexposed than on unexposed cultures. The results with unexposed cultures require confirmation by examination of more strains. Therefore, a longer PAE can be achieved by sub-MICs of gatifloxacin when they follow a suprainhibitory level (14, 15). In this study, preexposure concentrations of 4 and 10 times the MIC were within clinically achievable gatifloxacin levels for all strains (12), indicating that concentrations in serum would exceed the MICs for the entire recommended 24-h dosing interval. Our results suggest that a longer dosing interval may be possible for strains with a PAE and PA-SME, because bacterial regrowth would be prevented when levels in serum fall below the MICs.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by a grant from Bristol-Myers Squibb Laboratories, Wallingford, Conn.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psghs.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bauernfeind, A.
1997.
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
J. Antimicrob. Chemother.
40:639-651 |
| 2. | Cars, O., and I. Odenholt-Tornqvist. 1993. The postantibiotic subMIC effect in vitro and in vivo. J. Antimicrob. Chemother. 31:159-166. |
| 3. | Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):6-8. |
| 4. | Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams and Wilkins Co., Baltimore, Md. |
| 5. |
Ednie, L. M.,
M. R. Jacobs, and P. C. Appelbaum.
1998.
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrob. Agents Chemother.
42:2459-2462 |
| 6. |
Hoellman, D. B.,
G. Lin,
M. R. Jacobs, and P. C. Appelbaum.
1999.
Anti-pneumococcal activity of gatifloxacin compared to other quinolone and non-quinolone agents.
J. Antimicrob. Chemother.
43:645-649 |
| 7. |
Hosaka, M.,
S. Kinoshita,
A. Toyama,
M. Otsuki, and T. Nishino.
1995.
Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
J. Antimicrob. Chemother.
36:293-301 |
| 8. |
Hosaka, M.,
T. Yasue,
H. Fukuda,
H. Tomizawa,
H. Aoyama, and K. Hirai.
1992.
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Antimicrob. Agents Chemother.
36:2108-2117 |
| 9. |
Kato, N.,
H. Kato,
K. Tanaka-Bandoh,
K. Watanabe, and K. Ueno.
1997.
Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
J. Antimicrob. Chemother.
40:631-637 |
| 10. |
MacKenzie, F. M., and I. M. Gould.
1993.
The post-antibiotic effect.
J. Antimicrob. Chemother.
32:519-537 |
| 11. | Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C. |
| 12. | Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640[Abstract]. |
| 13. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 14. |
Odenholt-Tornqvist, I.
1993.
Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.
J. Antimicrob. Chemother.
31:881-892 |
| 15. |
Odenholt-Tornqvist, I,
E. Löwdin, and O. Cars.
1992.
Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
Antimicrob. Agents Chemother.
36:1852-1858 |
| 16. |
Wakabayashi, E., and S. Mitsuhashi.
1994.
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Antimicrob. Agents Chemother.
38:594-601 |
| 17. |
Wise, R.,
N. P. Brenwald,
J. M. Andrews, and F. Boswell.
1997.
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
J. Antimicrob. Chemother.
39:447-452 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»